Successful Treatment of Pediatric Generalized Pustular Psoriasis (GPP) with Spesolimab: 5 Case Reports and Evaluations of Circulating IL-36 Levels
Open Access
- 1 November 2024
- journal article
- research article
- Published by Taylor & Francis in Journal of Inflammation Research
- Vol. ume 17, 8199-8206
Abstract
Background: Generalized pustular psoriasis (GPP) is a rare, severe, and potentially life-threatening inflammatory cutaneous disease. IL-36 is a key treatment target in GPP. Spesolimab, a humanized monoclonal antibody of the IL-36 receptor, has demonstrated a good efficacy and a favorable safety profile in adults with GPP. However, data on its use in children are scarce. Methods: We treated patients aged 4– 12 years with GPP with a single dose of spesolimab. The Generalized Pustular Psoriasis Physician Global Assessment (GPPGA) total score, GPPGA pustulation sub-score, Generalized Pustular Psoriasis Area and Severity Index (GPPASI), and the Japanese Dermatological Association severity index for GPP were evaluated. The levels of IL-36α, IL-36β, and IL-36γ were detected by the magnetic bead-based immunoassays, and the levels of IL-17A, IL-17C, IFN-γ, TNF, IL-6, and IL-8 were measured by the Olink proximity extension assay technology. Results: We included five patients (four boys and one girl) with a median age was 6.9 years old (range: 4.8 to 10.6 years), and a median age of onset of 1.7 years (range: 3 months– 10 years and 5 months). After 1 week of spesolimab administration, all patients had a total GPPGA score of 0/1 and pustulation subscore of 0, all patients had a GPPASI of 50, and four patients had a GPPASI of 75. Meanwhile, plasma levels of IL-36α, IL-36β, IL-36γ, IL-17A, IL-17C, IFN-γ, TNF, IL-6, IL-8 all decreased, and those of IL-36α, IL-36β, IL-17A, IL-17C, and IL-6 were statistically significant. There was no recurrence after 2 to 8 months of treatment. No other adverse event was recorded apart from one patient who experienced an upper respiratory infection in the first week. Conclusion: Spesolimab might be a prospective option for children aged 4 to 12 years.Keywords
This publication has 24 references indexed in Scilit:
- Spesolimab for the Treatment of Generalized Pustular PsoriasisDrugs, 2023
- Efficacy and Safety of Spesolimab in Patients with Generalized Pustular Psoriasis: A Subgroup Analysis of Chinese Patients in the Effisayil 1 TrialDermatology and Therapy, 2023
- Efficacy and safety of subcutaneous spesolimab for the prevention of generalised pustular psoriasis flares (Effisayil 2): an international, multicentre, randomised, placebo-controlled trialThe Lancet, 2023
- The update of treatment strategies in pediatrics with generalized pustular psoriasis in ChinaPediatric Investigation, 2023
- Rapid and sustained improvements in Generalized Pustular Psoriasis Physician Global Assessment scores with spesolimab for treatment of generalized pustular psoriasis flares in the randomized, placebo-controlled Effisayil 1 studyJournal of the American Academy of Dermatology, 2023
- Treatments and outcomes of generalized pustular psoriasis: A cohort of 1516 patients in a nationwide inpatient database in JapanJournal of the American Academy of Dermatology, 2022
- Pathophysiology of Generalized Pustular PsoriasisAmerican Journal of Clinical Dermatology, 2022
- Trial of Spesolimab for Generalized Pustular PsoriasisNew England Journal of Medicine, 2021
- Generalized Pustular Psoriasis: Clinical Management and Update on Autoinflammatory AspectsAmerican Journal of Clinical Dermatology, 2019
- Clinical profiles of pediatric patients with GPP alone and with different IL36RN genotypesJournal of Dermatological Science, 2017